Role of an androgen receptor gene polymorphism in development of hormone refractory prostate cancer in Indian population.
BACKGROUND
Androgen receptors play critical roles in the development of primary as well as advanced hormone-refractory prostate cancers. Since the growth of prostate cancer is androgen-sensitive, metastatic disease has been treated by hormonal therapy in the form of androgen ablation. Prostate cancer cells rely on androgen receptor (AR) for proliferation and survival.


OBJECTIVE
To evaluate the prognostic significance of androgen receptor polymorphism in patients under hormonal therapy in any form.


METHODS
Complete follow up data were available for 87 patients out of 130 patients enrolled for study. DNA was extracted from blood samples using salting out method and then subjected to PCR Genscan for CAG and GGN genotyping. The mean follow up was 10.12+/-8.83 months.


RESULTS
Out of 87 patients, 64 experienced clinical as well as biochemical recurrence. The overall hormone refractory rates were 73.4% after one year. We observed a significant shorter median CAG repeats in HRPC patients (20 vs 22). The hazard ratio for HRPCs with the < or =20 CAG repeat genotype was 0.602 (0.33-1.08, p=0.09). Kaplan-Meier analysis showed that HRPC rates were not significantly associated with CAG repeat (p=0.06) but a trend was observed with short CAG repeats. No significant association was observed with AR-GGN repeats.


CONCLUSIONS
A trend for association of AR-CAG repeats with HRPC patients in north Indian population was observed, suggesting this to be a prognostic factor for determining the therapeutic regimen.
Mittal
Rama Devi
RD
Department of Urology, SGPGIMS, Lucknow, India. rmittal@sgpgi.ac.in
Mishra
Dhruva
D
Mandhani
Anil K
AK
D002455:Cell Division; D004273:DNA, Neoplasm / Q000097:blood / Q000235:genetics / Q000302:isolation & purification; D018572:Disease-Free Survival; D005838:Genotype; D006801:Humans; D007194:India / Q000453:epidemiology; D008297:Male; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000235:genetics* / Q000401:mortality; D011944:Receptors, Androgen / Q000235:genetics*; D017741:Survivors; D018911:Trinucleotide Repeats
D004273:DNA, Neoplasm; D011944:Receptors, Androgen